槲皮素對肝癌的影響

The effect of Quercetin in hepatocellular carcinoma

陳界甫(Jie-Fu Chen)

指導教授 ： 陳兆勛

國立臺灣大學/工學院/應用力學研究所/碩士(2012年)

https://doi.org/10.6342/NTU.2012.01719

摘要

肝癌在全世界是一種常見的癌症之一，在台灣也是導致許多癌症病患的死亡原因。為了提高肝癌病人的存活率，或降低手術過後的復發率，尋找有效的抗癌藥物是重要並且需要的。而廣泛存在於植物界的槲皮素因為具有抗癌變及抗增生的效果，且有強大的抗氧化能力以及在細胞訊號傳導、細胞週期、細胞凋亡的調控上有一定的能力而受到注意。本研究目的是希望藉由相關實驗，來觀察槲皮素是否能抑制人類肝癌細胞株Hep3B、Huh7，並以基因晶片做檢測分析，針對被調控到且會影響細胞增殖生長、細胞週期、細胞移動及細胞凋亡的基因做進一步探討，闡明槲皮素抑制人類肝癌細胞的藥理機制。此實驗以人類肝癌細胞株Hep3B及Huh7為材料進行體外培養，以各濃度槲皮素對細胞進行Proliferation、Colony formation、Wound-healing及Flow cytometry實驗，並以槲皮素影響效果較顯著的Huh7作進一步微陣列分析。實驗結果顯示，Hep3B及Huh7在48小時槲皮素濃度分別為500、50μM時，開始有顯著抑制細胞增殖效果；在濃度50、10μM時，顯著抑制細胞菌落發展；在同樣濃度100μM時，經過12小時就開始有顯著抑制細胞移動效果以及濃度分別在50、10μM能分別誘導Hep3B、Huh7產生細胞凋亡，且對細胞週期G1 phase都有阻滯效果，以上實驗效果都與槲皮素濃度成正相關；在來從進一步的Huh7微陣列分析實驗結果發現，槲皮素能調控Cell apoptosis、Cell cycle、Cell migration相關基因，而這些受到調控的基因可能參與了Apoptosis pathway、JAK/STAT、PI3K/AKT、MAPK/ERK pathway。而這些被影響調控的基因以及所參與的訊號傳導路徑就是槲皮素能夠抑制癌細胞生長增殖生長、細胞週期、細胞移動以及誘導凋亡背後最強而有力的證據。未來槲皮素或許可用於臨床上治療肝癌之輔助治療藥物，提高肝癌病人的存活率、降低化療藥物所產生的副作用以及降低手術過後的復發率。

關鍵字

肝癌 ； 槲皮素 ； 細胞凋亡 ； 細胞週期 ； 基因晶片

並列摘要

Hetapocellular carcinoma is one of the common cancers in the world, it is also the main reason that makes people die in the cancer. To increase the survival rate or reduce the recurrence rate, it is necessary and important to find those efficacious anti-cancer drugs. Quercetin is common existing in plant with great effect of anti-carcinogenesis and anti- proliferation. It also has good capability on anti-oxidant. Besides, Quercetin has been noticed by the abilities on effecting cell signal transduction and regulating of cell cycle and inducing cell apoptosis. The purpose of this research is trying to observe whether Quercetin can inhibit HCC cell growth by several experiments. Moreover, to find that the mechanism of inhibiting the proliferation、growth、cell cycle、migration and inducing apoptosis on HCC cell by Quercetin, we used microarray so that we can analyze the suppression effect on HCC cell by gene expression. This experiment uses HCC cell line- Hep3 and Huh7 as the materials in vitro culture, and different concentrations of Quercetin are using on experiments of Proliferation, Colony formation, Wound-healing and Flow cytometry. Huh7 is used on microarray analysis due to the better influence on Quercetin as well. Experiment results show that Hep3B and Huh7 have significantly inhibiting proliferation when the concentration of Quercetin is 500, 50μM on 48 hours; it also shows inhibition on colony formation while the concentration is 50、10μM. And Quercetin has good inhibition effect on cell migration after 12 hours when the concentration is 100μM, and it can also induce Hep3B、Huh7 apoptosis amd arrest G1 phase in cell cycle when the concentration is 50、10μM. All effect by Quercetin during the experiments is depending on the concentrations of Quercetin. Moreover, the experiment of microarray analysis for Huh7 also shows that Quercetin can regulate the gene relative to Apoptosis、cell cycle and migration。And these gene regulated by Quercetin may be involve Apoptosis pathway and several signal transduction pathway：JAK/STAT、PI3K/AKT、MAPK/ERK pathway. All the effect on signal transduction pathway or gene regulated by Quercetin are the strong evidence that Quercetin can inhibit the growing of cancer cells、arrest cell cycle、suppress cell migration and induce the apoptosis of cancer cells. Perhaps people can use Quercetin on clinical medicine for curing liver cancer, increase the survival rate and also decrease the side effect and recurrence rate.

並列關鍵字

Hetapocellular carcinoma ； Quercetin ； Apoptosis ； Cell cycle ； Microarray

參考文獻

[1] Vital Statistic: Taipei T, ROC: Department of Health, Executive Yuan,Health statistics of the Republic of China, 2005.

[2] Bosch, F. X., J. Ribes and J. Borras. 1999. Epidemiology of primary liver cancer. Semin. Liver Dis., 19: 271-285.

[3] Chen, C. J., M. H. Yu and Y. F. Liaw. 1997. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J. Gastroenterol Hepatol., 12: 294-300.

[4] Thomas, M.B., and Zhu, A.X. (2005). Hepatocellular carcinoma: the need for progress. J Clin Oncol 23, 2892-2899.

[5] Takano, S., Yokosuka, O., Imazeki, F., Tagawa, M. & Omata, M. (1995). Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 21, 650-5.